MedDataX Logo

Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

NCT ID: NCT04113941

Last Updated: 2020-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-23

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms

NCT04999657

Overactive Bladder
COMPLETED NA

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

NCT00335660

Overactive Bladder Syndrome
TERMINATED PHASE2

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

NCT02485067

Overactive Bladder
COMPLETED PHASE3

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

NCT03566134

Overactive Bladder
COMPLETED PHASE2

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects

NCT02821312

Overactive Bladder
UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neuronox®

Neuronox® total 100U, inject 5U/0.5mL per site, 20 sites

Group Type EXPERIMENTAL

Neuronox

Intervention Type DRUG

intradetrusor injection

Placebo

Normal saline, same volume with Experimental arm

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

intradetrusor injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuronox

intradetrusor injection

Intervention Type DRUG

Placebo

intradetrusor injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Meditoxin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects aged above 20
* Patient with overactive bladder symptoms lasting at least 6 months

Exclusion Criteria

* Patient with a history of surgery or a disease that may affect bladder function.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medy-Tox

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Konkuk University Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MT01-KR17OAB302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
NCT03482037 COMPLETED PHASE1/PHASE2
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
NCT00196404 COMPLETED PHASE2
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
NCT00231790 COMPLETED PHASE2
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636 COMPLETED PHASE3
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
NCT02240459 COMPLETED PHASE2
Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.
NCT04483817 UNKNOWN NA
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
NCT01314872 COMPLETED PHASE2
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
NCT00290563 COMPLETED PHASE2
Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome
NCT01824420 COMPLETED PHASE4
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 UNKNOWN PHASE4
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
NCT01192568 COMPLETED PHASE4
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
NCT00439192 TERMINATED PHASE2
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
NCT01302067 COMPLETED PHASE4
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
NCT05282069 COMPLETED PHASE3
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
NCT03492281 COMPLETED PHASE3
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
NCT00629642 COMPLETED PHASE4
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 COMPLETED PHASE4
Study of V117957 in Overactive Bladder Syndrome
NCT06024642 COMPLETED PHASE1
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
NCT00139724 COMPLETED PHASE3
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
NCT03175029 COMPLETED PHASE2
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
NCT00911937 COMPLETED PHASE4
Fesoterodine Flexible Dose Study
NCT00536484 COMPLETED PHASE3
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
NCT00561951 COMPLETED PHASE2
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666 COMPLETED PHASE3
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
NCT00798434 COMPLETED PHASE4